Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hradec Králové, Czechia, 500 12
- University Hospital Hradec Kralove
-
-
-
-
-
Bordeaux, France, 33075
- Hopital Saint André
-
Le Mans, France, 72037
- Centre Hospitalier Le Mans
-
Marseille, France, 13274
- Hôpital Sainte Marguerite
-
-
-
-
-
Münster, Germany, 48149
- Klinik und Poliklinik für Hautkrankheiten
-
-
-
-
-
Milano, Italy, 20141
- Istituto Europeo di Oncologia
-
-
-
-
-
Moscow, Russian Federation, 115478
- N.N.Blokhin Russian Cancer Research Centre
-
-
-
-
-
Valencia, Spain, 46014
- Hospital General de Valencia
-
-
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Blumenthal Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main inclusion criteria include:
- Patient with histologically or cytologically confirmed non-resectable or metastatic stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanoma
- Patient with detectable c-Kit JM mutation (mutation in exon 9, 11 or 13) confirmed by DNA or RNA sequencing, which is expected to be mainly found after screening of mucosal or acral melanoma or melanoma on skin with chronic sun-induced damages (defined by a microscopically marked elastosis involving the skin surrounding their primary melanoma).
- Patient not previously treated for melanoma (first-line)
Main exclusion criteria include:
- Pregnant, or nursing female patient
- Patient with active brain metastases.
- Prior treatment with a tyrosine kinase c-Kit inhibitor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Masitinib
Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
|
Masitinib 7.5 mg/kg/day
Other Names:
|
|
Active Comparator: Dacarbazine
Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks.
Following a protocol amendment, the dacarbarzine treatment group has been closed
|
IV bolus at 1,000 mg/m2 once every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate
Time Frame: 24 weeks
|
Estimated as the number of patients with documented partial response or complete response defined according to the RECIST criteria, divided by the number of randomized patients
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival (OS)
Time Frame: From day of randomization to death, assessed for a maximum of 60 months
|
Overall survival is defined as time in months from the randomization date to the date of death due to any cause.
If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.
|
From day of randomization to death, assessed for a maximum of 60 months
|
|
PFS
Time Frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months
|
Progression Free Survival (PFS) is defined as the delay between the date of randomization to the date of documented progression (according to RECIST) or any cause of death during the study.
|
From day of randomization to disease progression or death, assessed for a maximum of 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jean-Jacques GROB, MD, PhD, Hôpital Sainte Marguerite, Marseille, France
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Dacarbazine
Other Study ID Numbers
Other Study ID Numbers
- AB08026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.